EntreMed, Inc, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, said it presented the preclinical and mechanism of action data for its selective kinase inhibitor, ENMD-2076 at the American Association for Cancer Research (AACR) annual meeting in San Diego, California.
During the presentation, Dr. Bray highlighted ENMD-2076's unique combination of antiangiogenic, cell cycle, and antiproliferative activities. In preclinical studies, ENMD-2076 demonstrated potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumour regression in breast, colon, and leukaemia models. ENMD-2076 is an orally active, multi-kinase inhibitor that has shown an acceptable toxicity profile in multiple preclinical studies without cardiovascular effects.
ENMD-2076 is an exciting compound with demonstrated single-agent activity against a broad range of tumour types. EntreMed recently commenced a phase I, dose-escalation study with ENMD-2076 in advanced cancers and plans to initiate a second phase I study in haematological cancers later in 2008.